Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis.
about
Cloning and characterization of a second complementary DNA for human tryptaseTryptase genetics and anaphylaxisManagement and Prevention of AnaphylaxisMast cell dependent vascular changes associated with an acute response to cold immersion in primary contact urticariaFate of two mast cell tryptases in V3 mastocytosis and normal BALB/c mice undergoing passive systemic anaphylaxis: prolonged retention of exocytosed mMCP-6 in connective tissues, and rapid accumulation of enzymatically active mMCP-7 in the bloodHuman tryptase epsilon (PRSS22), a new member of the chromosome 16p13.3 family of human serine proteases expressed in airway epithelial cells.Antibody against immunoglobulin E contained in blood components as causative factor for anaphylactic transfusion reactions.Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: possible biological-clinical significance.Desensitization protocols for vancomycin hypersensitivity.Mast cell proteases as pharmacological targetsMast cell tryptase and carboxypeptidase A expression in body fluid and gastrointestinal tract associated with drug-related fatal anaphylaxis.Improving diagnostic accuracy of anaphylaxis in the acute care setting.A novel model of IgE-mediated passive pulmonary anaphylaxis in rats.Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis.Characterisation of immune mediator release during the immediate response to segmental mucosal challenge in the jejunum of patients with food allergy.Postmortem findings after fatal anaphylactic reactionsEarly detection of allergic diseases in otorhinolaryngologyProposed use of adrenaline (epinephrine) in anaphylaxis and related conditions: a study of senior house officers starting accident and emergency posts.Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patientsActivation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases.Enhanced basophil reactivities during severe malaria and their relationship with the Plasmodium falciparum histamine-releasing factor translationally controlled tumor proteinDrug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.Pathogenic role of cardiac mast cell activation/degranulation,TNF-alpha, and cell death in acute drug-related fatalitiesMast cell tryptase and asthma.Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy.Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma.Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains.T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment.Food-induced anaphylaxis: mast cells as modulators of anaphylactic severity.Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance.Tryptase as an inflammatory marker in allergic disease and asthma.Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.Anaphylaxis as a clinical manifestation of clonal mast cell disorders.Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.Optimal treatment of anaphylaxis: antihistamines versus epinephrine.Management of angioedema without urticaria in the emergency department.An approach to iatrogenic deaths.How to interpret mast cell tests.Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.
P2860
Q24295001-2BB0B63E-4FA3-4A4C-8D59-FF3257A0C273Q24650684-EB6DBA01-D2E3-40CF-A691-AE5ABEC4045BQ26766190-B7F69512-84BC-43A8-8527-20FC73ED13DAQ27314006-DF7E762D-AE40-4A61-930C-EECEF09118A0Q28592892-28B1A3C3-F039-42AB-B58D-46C7ADB6227BQ30328729-0B69D8AE-34F6-4473-A7D3-2E76A694AC7BQ33413628-75CE80DB-17CA-484A-AAE4-5616A53235EDQ33734545-036430E0-FE84-48BD-ADCF-66DF5C6A8A0BQ34449467-1949239C-40B9-468E-B66E-838E28260CC7Q34475790-A9B3863C-E6CF-42BE-9FBE-73628AF7C8E9Q34506923-6F59CD5E-9785-450C-A7E1-2DE2ECC67A0AQ34522907-B23E3682-3390-4AD8-A119-B53CAFC89D44Q34777137-EB2052BA-2A0B-4B25-AAE1-5098ECA527D9Q35134181-4425DC16-3C27-4D0A-BA3E-765BCB34BC75Q35357190-0F1F8703-1398-4EA4-AE23-546D76F61B13Q35396095-C134FEA5-387A-475F-B9B5-9D860FC8F4EDQ35427549-75F7E8DD-473E-402E-AECC-188EB7344BF1Q35514613-CD8506C4-4EE6-4374-B80A-F52E14AB0405Q35625455-5C874298-DAEB-4597-A0CF-9B70D9130648Q35970392-2E3FA569-B9B1-4B86-AEAF-542A48A6E90DQ36211115-DF0DE4C8-549E-4767-8397-E7DD1A472AF7Q36577123-84F2F7CF-73F2-4CFF-998C-2B951F9D598BQ36596917-43B144FF-606F-459A-A23E-9D33BF7FB30AQ37160335-DC581A2A-12D7-4374-B6ED-DF824A56BD7BQ37199242-84548DBF-37F4-48AB-A9DD-52C5CD777A52Q37304874-878F6249-CF7A-40E0-8312-5A1A6878CB49Q37364326-3739CF4C-BC6C-42AB-95FC-79C5B609AE89Q37466219-390E32DD-B21C-429B-8BAE-ED56E1C395B3Q37560995-D7057F27-AD01-4498-AB8D-63F07FC7CAC4Q37585269-DABB9C83-0B4A-45D4-A7DD-7F8BDED84E82Q37617482-41E29EC7-EEC8-444D-8140-B5E824F9FF8DQ37755301-111C8E1C-1089-4723-8B0A-A64D4A6C1EA7Q37873485-253D150D-FF71-4C2C-AE84-997001E25E7BQ38221739-7D642AAC-73B0-4F6E-8619-058700D262BFQ38222050-29CC4875-9DFB-496B-A469-448F204D09F0Q38241636-257BBBAE-01F5-489F-BFFF-01E17B4FED84Q38314955-BC2DF783-31B8-4CEB-8593-8142ECD23F77Q38714784-58E19AF5-19C3-40AD-9BA2-673FF5338545Q38850401-11504FC0-9EC4-4023-898C-D8A4A517995EQ38859163-36B1404B-6B94-44AD-B26D-8D9E25192AF9
P2860
Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Time course of appearance and ...... circulation after anaphylaxis.
@ast
Time course of appearance and ...... circulation after anaphylaxis.
@en
Time course of appearance and ...... circulation after anaphylaxis.
@nl
type
label
Time course of appearance and ...... circulation after anaphylaxis.
@ast
Time course of appearance and ...... circulation after anaphylaxis.
@en
Time course of appearance and ...... circulation after anaphylaxis.
@nl
prefLabel
Time course of appearance and ...... circulation after anaphylaxis.
@ast
Time course of appearance and ...... circulation after anaphylaxis.
@en
Time course of appearance and ...... circulation after anaphylaxis.
@nl
P2093
P2860
P356
P1476
Time course of appearance and ...... circulation after anaphylaxis.
@en
P2093
P2860
P304
P356
10.1172/JCI114051
P407
P577
1989-05-01T00:00:00Z